Medical Communications
Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment
November 27, 2023 Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment
November 27, 2023 Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma
Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment
November 23, 2023 Medical Communications Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis
GSK’s low carbon inhaler, Ventolin, progresses to phase 3 trialsÂ
November 21, 2023 Medical Communications Asthma & COPD, GSK, Ventolin, asthma, carbon-neutral
Almirall gains EC approval of Ebglyss for moderate-to-severe atopic dermatitis
November 20, 2023 Medical Communications Almirall, Dermatology, Ebglyss, European Commission, atopic dermatitis
FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment
November 17, 2023 Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer
FDA approves Merck’s Keytruda for gastric cancer treatment
November 17, 2023 Medical Communications FDA, MSD, Merck, Oncology, gastric cancer, keytruda
FDA approves BMS’s Augtyro for lung cancer treatment
November 16, 2023 Medical Communications FDA, Oncology, bristol myers squibb, lung cancer
Kesin Pharma’s Likmez approved by FDA
November 15, 2023 Medical Communications Kesin Pharma, Likmez, Pharmacy, Saptalis Pharmaceuticals, antibiotic
Alvotech and JAMP Pharma’s Jamteki gains marketing authorisation from Health Canada
November 15, 2023 Medical Communications Alvotech, Health Canada, JAMP Pharma, Pharmacy, biosimilar
Health Canada approves Ipsen and Medision Pharma’s Bylvay for pruritus treatment
November 14, 2023 Medical Communications Health Canada, Medision Pharma, Rare Diseases, ipsen, pruritis
GSK gains positive CHMP opinion for momelotinib for myelofibrosis treatment
November 13, 2023 Medical Communications CHMP, GSK, Haematology, anaemia, momelotinib, myelofibrosis
Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment
November 10, 2023 Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia
Eli Lilly’s Zepbound approved by FDA for chronic weight management
November 9, 2023 Medical Communications Eli Lilly, FDA, Obesity, Zepbound, weight loss, weight management
Bit.bio announces cell therapy pipeline
November 8, 2023 Medical Communications Hepatology, bit.bio, cell therapy, liver failure
Latest content
